Reneuron (RENE.L) is a stem cell research company whose focus is on therapies targeting areas of poorly met medical need, including peripheral arterial disease, stroke, and retinal diseases. RENE is currently testing the effects of neural stem cells on spines for neuroregeneration, and is testing the use of fetal stem cells on stroke patients.
A UK company, used as a scientific comparable due to status of trials and disease state.
July 14, 2016
RegMed investors’ closing bell analysis: another positive open and a negative close, the sector’s flashing caution
July 12, 2016
RegMed investors’ closing bell analysis: tripping to the upside
July 11, 2016
RegMed investors’ closing bell analysis: after four (4) up sessions, the fix was in
July 8, 2016
RegMed investors’ closing bell analysis: collateral damage was not bad as sector shakes off JUNO’s news
July 7, 2016
RegMed investors’ closing bell analysis: the upside waivered at the mid-day regaining ground at the close
July 6, 2016
RegMed investors’ closing bell analysis: a revolving sector and a positive close
July 5, 2016
RegMed investors’ closing bell analysis: sector loses its footing
June 28, 2016
RegMed investors’ closing bell analysis: a ripple effect
June 27, 2016
RegMed investors’ closing bell analysis: sweating the sell-off damage
June 24, 2016
RegMed investors’ closing bell analysis: two words anticipated and stampede
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.